Friedenthal Financial Raises Stake in Insulet Corporation (NASDAQ:PODD)

Friedenthal Financial boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 1,400.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,301 shares of the medical instruments supplier's stock after purchasing an additional 3,081 shares during the period. Friedenthal Financial's holdings in Insulet were worth $867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PODD. Horizon Investments LLC increased its holdings in Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after buying an additional 42 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in Insulet by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after acquiring an additional 48 shares in the last quarter. Steward Partners Investment Advisory LLC grew its stake in Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock valued at $274,000 after acquiring an additional 50 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Insulet by 2.4% during the 4th quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock valued at $566,000 after acquiring an additional 50 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its stake in Insulet by 4.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock valued at $285,000 after acquiring an additional 51 shares in the last quarter.

Insider Activity

In related news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Stock Up 0.5%

Insulet stock traded up $1.36 during mid-day trading on Friday, reaching $303.15. 1,539,107 shares of the company's stock were exchanged, compared to its average volume of 717,137. The company has a market cap of $21.34 billion, a P/E ratio of 54.52, a P/E/G ratio of 2.69 and a beta of 1.37. Insulet Corporation has a twelve month low of $173.00 and a twelve month high of $329.33. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21. The company has a fifty day moving average of $291.86 and a 200-day moving average of $276.20.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm's quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 EPS. Sell-side analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on PODD shares. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Stifel Nicolaus upped their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research note on Friday, February 21st. The Goldman Sachs Group started coverage on shares of Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 price objective for the company. Canaccord Genuity Group upped their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Piper Sandler upped their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.